Close Menu

A news piece in this week's Science reports that ECell International (ESI), a Singapore-based company, is stopping research work on human embryonic stem cells due to increasing lack of investor interest. The time lag from lab to clinic is too long, investors say, but several companies, including Geron and ACT, are not giving up, claiming they have products in the pipeline.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.